EGFR and neoplasm: Receptor degradation mediated by the PAbs, along with inhibition of their phosphorylation, was translated into an enhanced impairment of cell viability regarding MAbs combinations in tumor lines overexpressing wild-type or mutated variants of HER1, as well as cetuximab-tolerant cells.